Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38(1):7-41. https://pubmed.ncbi.nlm.nih.gov/24636754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992879 https://doi.org/10.1016/j.currproblcancer.2014.01.001

Sohail S, Shafiq W, Raza SA, Zahid A, Mir K, Azmat U. Clinical characteristics and outcome of patients with pheochromocytoma: a single center tertiary care experience. Cureus. 2020;12(5):e7990. https://pubmed.ncbi.nlm.nih.gov/32523845 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274258 https://doi.org/10.7759/cureus.7990

Lenders JWM, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. https://pubmed.ncbi.nlm.nih.gov/24893135 https://doi.org/10.1210/jc.2014-1498

Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355-61. https://pubmed.ncbi.nlm.nih.gov/19497985 https://doi.org/10.1530/EJE-09-0384

Aggarwal S, Prete A, Chortis V, et al. Pheochromocytomas most commonly present as adrenal incidentalomas: a large tertiary center experience. J Clin Endocrinol Metab. 2023;109(1):e389-96. https://pubmed.ncbi.nlm.nih.gov/37417693 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735286 https://doi.org/10.1210/clinem/dgad401

Uslar T, San Francisco IF, Olmos R, et al. Clinical presentation and perioperative management of pheochromocytomas and paragangliomas: a 4-decade experience. J Endocr Soc. 2021;22;5(10):bvab073. https://pubmed.ncbi.nlm.nih.gov/34377881 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336720 https://doi.org/10.1210/jendso/bvab073

Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29(5):1133-9. https://pubmed.ncbi.nlm.nih.gov/9149678 https://doi.org/10.1161/01.hyp.29.5.1133

Beninato T, Kluijfhout WP, Drake FT, et al. Resection of pheochromocytoma improves diabetes mellitus in the majority of patients. Ann Surg Oncol. 2017;24(5):1208-13. https://pubmed.ncbi.nlm.nih.gov/27896511 https://doi.org/10.1245/s10434-016-5701-6

Kim JH, Moon H, Noh J, Lee J, Kim SG. Epidemiology and prognosis of pheochromocytoma/paraganglioma in Korea: a nationwide study based on the National Health Insurance Service. Endocrinol Metab (Seoul). 2020;35(1):157-64. https://pubmed.ncbi.nlm.nih.gov/32207276 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090309 https://doi.org/10.3803/EnM.2020.35.1.157

Mesmar B, Poola-Kella S, Malek R. The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature. Endocr Pract. 2017;23(8):999-1005. https://pubmed.ncbi.nlm.nih.gov/28613940 https://doi.org/10.4158/EP171914.RA

van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg. 1990;14(3):325-9. https://pubmed.ncbi.nlm.nih.gov/1973322 https://doi.org/10.1007/BF01658516

Parasiliti-Caprino M, Lucatello B, Lopez C, et al. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertens Res. 2020;43(6):500-10. https://pubmed.ncbi.nlm.nih.gov/31586159 https://doi.org/10.1038/s41440-019-0339-y

Amar L, Fassnacht M, Gimenez-Roqueplo AP, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44(5):385-9. https://pubmed.ncbi.nlm.nih.gov/22351478 https://doi.org/10.1055/s-0031-1301339

Plouin PF, Amar L, Dekkers OM, et al. Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1-10. https://pubmed.ncbi.nlm.nih.gov/27048283 https://doi.org/10.1530/EJE-16-0033